Warren Gen. Hosp. v. Amgen, Inc., No. 10-2778 (3d Cir. 2011)
Annotate this CaseThe hospital filed the proposed class action, alleging that the pharmaceutical company violate antitrust "tying" prohibitions by using its knowledge of insurance reimbursement rates to leverage its market power in one market—White Blood Cell Growth Factor drugs—to impair competition in the market for Red Blood Cell Growth Factor drugs (Sherman Act, 15 U.S.C. 1 and Clayton Act, 15 U.S.C. 14, 15). The district court dismissed on the ground that the hospital was not a "direct purchaser." The Sixth Circuit affirmed. The mechanics of the hospital's contracts for acquiring the drugs show it to be an indirect purchaser that placed orders and received the drugs through a middleman, despite some direct communications between the manufacturer and the hospital and a rebate program between the two. The court rejected the hospital's claim that it should be granted standing as the first party in the distribution chain to suffer injury from the anti-competitive conduct.
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.